Century Therapeutics, Inc. (IPSC)
NASDAQ: IPSC · Real-Time Price · USD
0.6256
-0.0341 (-5.17%)
At close: Jul 25, 2025, 4:00 PM
0.6165
-0.0091 (-1.45%)
After-hours: Jul 25, 2025, 7:31 PM EDT

Century Therapeutics Stock Forecast

IPSC's stock price has decreased by -73.71% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 5 analysts that cover Century Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $3.33, which forecasts a 432.29% increase in the stock price over the next year. The lowest target is $2 and the highest is $6.

Price Target: $3.33 (+432.29%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$2.00$3.33$2.00$6.00
Change+219.69%+432.29%+219.69%+859.08%
* Price targets were last updated on May 16, 2025.

Analyst Ratings

The average analyst rating for Century Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingFeb '25Mar '25Apr '25May '25Jun '25Jul '25
Strong Buy444444
Buy111111
Hold000000
Sell000000
Strong Sell000000
Total555555

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Chardan Capital
Chardan Capital
Strong Buy
Maintains
$7$6
Strong BuyMaintains$7$6+859.08%May 16, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Maintains
$5$2
Strong BuyMaintains$5$2+219.69%Apr 3, 2025
Guggenheim
Guggenheim
Strong Buy
Reiterates
n/a
Strong BuyReiteratesn/an/aMar 28, 2025
Chardan Capital
Chardan Capital
Strong Buy
Maintains
$11$7
Strong BuyMaintains$11$7+1,018.93%Mar 24, 2025
Guggenheim
Guggenheim
Strong Buy
Maintains
$12$5
Strong BuyMaintains$12$5+699.23%Mar 21, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
111.36M
from 6.59M
Increased by 1,590.09%
Revenue Next Year
n/a
from 111.36M
EPS This Year
-0.28
from -1.61
EPS Next Year
-1.44
from -0.28
Fiscal YearFY 2020FY 2021FY 2022FY 2023FY 2024FY 2025FY 2026FY 2027
Period EndingDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026Dec 31, 2027
Revenue
--5.20M2.24M6.59M111.36M--
Revenue Growth
----57.01%194.81%1,590.09%--
EPS
-7.16-2.96-2.27-2.30-1.61-0.28-1.44-1.45
EPS Growth
--------
Forward PE
--------
No. Analysts
-----884
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue20252026202720282029
High114.7Mn/an/a
Avg111.4Mn/an/a
Low107.0Mn/an/a

Revenue Growth

Revenue Growth20252026202720282029
High
1,640.2%
--
Avg
1,590.1%
--
Low
1,523.6%
--

EPS Forecast

EPS202520262027
High-0.14-0.64-1.31
Avg-0.28-1.44-1.45
Low-0.35-1.75-1.56

EPS Growth

EPS Growth202520262027
High---
Avg---
Low---
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.